Sharemaestro company-news research for Veradermics, Incorporated (MANE), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NYSE
United States
Insufficient evidence
Company news sentiment
Latest MANE news and sentiment
Veradermics, Incorporated
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
No current company-news score
No company-specific headline in the last 30 days currently passes the date and relevance checks. The dash means no score; it is not a neutral observation.
Observed headline tone50/100
โ
Published 30-day score50/100
Latest source headline
Veradermics๏ผNYSE: MANE๏ผใ็พ้ใ่ณขๆใซๆดป็จใใใใจใๆๅพ
ใใฆใใพใใ
Moomoo ยท 26 Sep 2026 12:21
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
Available information
7 current stories are mapped specifically to MANE.
Why there is no score
The stories agree, but freshness-weighted evidence is only 0.000.
Confidence is 0/100, below the threshold for a firm score.
โ/100
News scoreNo qualifying directional evidence
0/100
Confidencethin evidence
0%/100
Company news7 company stories
100/100
Story agreement0/100 difference
News history
Daily score and story count over 30 days
31 Aug15 Sep29 Sep
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence0
0.0 after freshness weightingSource breadth0
0 independent publishersCompany relevance0
share tied directly to this companyFreshness49
recency-weighted evidenceAgreement100
how closely stories agreePublisher mix0
less reliance on one publisherPrice and news history
Weekly price and news-score history
No sufficiently fresh, directly relevant company news is available for a price comparison.
26 completed price weeks14 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
03 Apr30 Jun25 Sep
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
25 Sep 202650USD 116.57+9.2%
18 Sep 202651USD 106.75+7.9%
11 Sep 202651USD 98.97+0.5%
04 Sep 202649USD 98.51+0.6%
28 Aug 202647USD 97.93-4.8%
21 Aug 202646USD 102.82-8.8%
14 Aug 202650USD 112.71-1.5%
07 Aug 202646USD 114.39+8.9%
Insufficient evidence
News subjects
What is shaping the score
Market update506 stories ยท 86%
Analyst action501 stories ยท 14%
Source mix
Where the evidence comes from
Simply Wall St.522 stories ยท 29%
MarketBeat502 stories ยท 29%
Moomoo501 stories ยท 14%
Kalkine Media501 stories ยท 14%
Business Wire501 stories ยท 14%
Recurring subjects
Subjects appearing most often
Life Sciences3Earnings3Financial Markets2Finance2
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
21 Jun50 neutral26 Sep 23:59
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 26 Sep 23:59 | 50 | +0 | 16/100 (-1) | 10 (-4) | Provisional |
| 22 Sep 23:59 | 50 | +0 | 17/100 (-1) | 14 (0) | Provisional |
| 21 Sep 23:59 | 50 | -1 | 18/100 (-12) | 14 (-24) | Provisional |
| 09 Sep 23:59 | 51 | +2 | 30/100 (+12) | 38 (0) | Provisional |
| 05 Sep 23:59 | 49 | +0 | 18/100 (0) | 38 (-1) | Provisional |
| 04 Sep 23:59 | 49 | +0 | 18/100 (-1) | 39 (+1) | Provisional |
| 03 Sep 23:59 | 49 | +0 | 19/100 (0) | 38 (+1) | Provisional |
| 02 Sep 23:59 | 49 | +0 | 19/100 (-1) | 37 (0) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 7 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
No directional evidence to attribute yet
Company news can still be read below. Influence bars appear when a current story qualifies for the directional score.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
Market updateNot used in direction
Veradermics๏ผNYSE: MANE๏ผใ็พ้ใ่ณขๆใซๆดป็จใใใใจใๆๅพ ใใฆใใพใใ
ใใฎ่จไบใฏใVeradermics๏ผNYSE: MANE๏ผใไฟๆใใ็พ้ใจใใใฎ่ณ้ใใฉใฎใใใซๆดป็จใใใใซใคใใฆใฎๆๅพ ใซใคใใฆ่ฟฐในใฆใใใใใงใใใใ ใใๆไพใใใใณใณใใณใใ้ๅธธใซ็ญใใใใๅ ทไฝ็ใชๅ ๅฎนใซใคใใฆใฏไธๆใงใใ
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
ใใฎ่จไบใฏใVeradermics๏ผNYSE: MANE๏ผใไฟๆใใ็พ้ใจใใใฎ่ณ้ใใฉใฎใใใซๆดป็จใใใใซใคใใฆใฎๆๅพ ใซใคใใฆ่ฟฐในใฆใใใใใงใใใใ ใใๆไพใใใใณใณใใณใใ้ๅธธใซ็ญใใใใๅ ทไฝ็ใชๅ ๅฎนใซใคใใฆใฏไธๆใงใใ
- Published
- 26 Sep 2026 12:21
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company ยท 100%
- How it is used
- Shown as company news ยท not used in the score
- Story strength
- Not directional
- 30-day weight
- None ยท 2.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
FinanceLife Sciences
—Unscored
Market updateNot used in direction
Veradermics (NYSE:MANE) Trading 6.1% Higher - What's Next?
Veradermics (NYSE:MANE) stock increased by 6.1% to $119.64 during midday trading on Tuesday, September 22, 2026, despite a 75% decrease in trading volume compared to the average session. Analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average price targetโฆ
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Veradermics (NYSE:MANE) stock increased by 6.1% to $119.64 during midday trading on Tuesday, September 22, 2026, despite a 75% decrease in trading volume compared to the average session. Analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average price target of $153.00. While insiders sold a significant number of shares, institutional investors, including Wellington Management and Seven Fleet Capital, have either established or increased their positions in the company.
- Published
- 22 Sep 2026 15:52
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company ยท 100%
- How it is used
- Shown as company news ยท not used in the score
- Story strength
- Not directional
- 30-day weight
- None ยท 6.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Analyst actionNot used in direction
Veradermics, Incorporated (NYSE:MANE) Receives Consensus Rating of "Moderate Buy" from Brokerages
Veradermics, Incorporated (NYSE:MANE) has received a consensus "Moderate Buy" rating from brokerages, with seven out of nine analysts recommending a buy, and an average 12-month price target of $153.00. Despite strong institutional interest and in-line quarterly earnings, insiders have reโฆ
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Veradermics, Incorporated (NYSE:MANE) has received a consensus "Moderate Buy" rating from brokerages, with seven out of nine analysts recommending a buy, and an average 12-month price target of $153.00. Despite strong institutional interest and in-line quarterly earnings, insiders have recently sold a significant number of shares totaling over $103 million. The company's stock opened at $107.16, with a market cap of $4.48 billion and a P/E ratio of -56.40.
- Published
- 21 Sep 2026 08:24
- News subject
- Analyst action
- Why this score
- Business expansion, Institutional or insider selling
- Company focus
- Main company ยท 100%
- How it is used
- Shown as company news ยท not used in the score
- Story strength
- Not directional
- 30-day weight
- None ยท 7.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Hollander David Receives 9,650 Shares and 19,300 Derivative Securities from Veradermics on September 1, 2026
Hollander David, Chief R&D Officer at Veradermics, Inc., was granted 9,650 shares and 19,300 derivative securities on September 1, 2026. These transactions, recorded with SEC code A, have updated his ownership stake in the company. His post-transaction holdings now accurately reflect thesโฆ
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Hollander David, Chief R&D Officer at Veradermics, Inc., was granted 9,650 shares and 19,300 derivative securities on September 1, 2026. These transactions, recorded with SEC code A, have updated his ownership stake in the company. His post-transaction holdings now accurately reflect these awards, providing transparency for investors.
- Published
- 04 Sep 2026 23:20
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company ยท 100%
- How it is used
- Shown as company news ยท not used in the score
- Story strength
- Not directional
- 30-day weight
- None ยท 24.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinance
—Unscored
Market updateNot used in direction
Veradermics to Present at Upcoming September Investor Conferences
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 03 Sep 2026 21:33
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company ยท 100%
- How it is used
- Shown as company news ยท not used in the score
- Story strength
- Not directional
- 30-day weight
- None ยท 25.1d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Veradermics (MANE) Stock Looks Overvalued After Its 161% Rally
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 03 Sep 2026 01:06
- News subject
- Market update
- Why this score
- Negative valuation view
- Company focus
- Main company ยท 100%
- How it is used
- Shown as company news ยท not used in the score
- Story strength
- Not directional
- 30-day weight
- None ยท 26.0d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Is Veradermics (MANE) Still Undervalued After Its 161% Year To Date Run?
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 02 Sep 2026 22:15
- News subject
- Market update
- Why this score
- Positive valuation view
- Company focus
- Main company ยท 100%
- How it is used
- Shown as company news ยท not used in the score
- Story strength
- Not directional
- 30-day weight
- None ยท 26.1d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
Earlier company news
MANE news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 83 older MANE headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to MANE, but the headline and available text are not mainly about Veradermics, Incorporated. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of MANE sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.